MultiOmic Health announces discovery of novel endotypes and biomarkers for diabetic kidney disease
MultiOmic Health, a leading AI-enabled drug discovery company, announces the identification of novel patient endotypes and the development of proprietary biomarkers for stratifying diabetic kidney disease (DKD) patients.
MultiOmic Health to Present at Bio€quity Europe 2024
We’re thrilled to announce our participation at #BioEquityEurope 2024!
Robert Thong, our CEO at MultiOmic Health, will be presenting on our innovative approach to tackle cardiorenal complications. Join us for insights into how we aim to transform the landscape of metabolic syndrome through precision medicine.
MultiOmic Health and Queen’s University Belfast join forces to transform diabetic kidney disease diagnosis
MultiOmic Health, an artificial intelligence (AI)-enabled drug discovery company, is embarking on a collaborative project with the Centre for Public Health at Queen’s University Belfast (QUB) in Northern Ireland to develop data-driven diagnostic tools for Diabetic Kidney Disease (DKD).
A paper by the MultiOmic team members was published in the May issue of the ICT magazine
What insight can recent trials give us into how molecular-level disease drivers can be used to enter into a new era of precision nephrology?
MultiOmic Health Closes $6.2 Million Funding Round to Discover Precision Medicines for Metabolic Syndrome-Related Conditions
MultiOmic Health has closed a £5 million seed extension round to build its precision therapeutics discovery platform for metabolic syndrome.
MultiOmic Health forges research collaboration with Northern Care Alliance NHS Foundation Trust in diabetic kidney disease
MultiOmic Health forges research collaboration with Northern Care Alliance NHS Foundation Trust in diabetic kidney disease
Honoured to be selected as winners of BIA’s Innovation Showcase in the first ever TechBioUK conference
MultiOmic is proud to announce winning first place in the pitch competition at BIA’s TechBio UK Conference 2022
Leveraging AI to Tackle the Looming Metabolic Syndrome Crisis
In this article, we look at how Mesh Bio and MultiOmic Health use AI to transform and improve the lives of metabolic syndrome patients through patient stratification and precision medicine.
Understanding the AI-enabled Drug Discovery Landscape
An Expert View from Henrietta Bull, science and partnership analyst, and Robert Thong, chief executive, MultiOmic Health.
The Pharma Letter Podcast — Episode 15 — Can AI find new drugs for metabolic diseases?
In this week’s episode of The Pharma Letter Podcast, MultiOmic chief executive Robert Thong discusses his firm’s progress and ambitions for the future.